Recce Pharmaceuticals (ASX:RCE) Interest Expense : A$-0.44 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Recce Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Recce Pharmaceuticals's interest expense for the six months ended in Dec. 2023 was A$ -0.27 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.44 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Recce Pharmaceuticals's Operating Income for the six months ended in Dec. 2023 was A$ -9.54 Mil. Recce Pharmaceuticals's Interest Expense for the six months ended in Dec. 2023 was A$ -0.27 Mil. Recce Pharmaceuticals did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Recce Pharmaceuticals Interest Expense Historical Data

The historical data trend for Recce Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recce Pharmaceuticals Interest Expense Chart

Recce Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

-0.06

-0.05

-0.17

Recce Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial											-	-	-	-0.17	-0.27

Recce Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.44 Mil.

Recce Pharmaceuticals (ASX:RCE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Recce Pharmaceuticals's Interest Expense for the six months ended in Dec. 2023 was A$-0.27 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-9.54 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was A$0.08 Mil.

Recce Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Recce Pharmaceuticals did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Recce Pharmaceuticals (ASX:RCE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recce Pharmaceuticals Ltd (ASX:RCE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

R9Q:Germany

Address

180 George Street, Level 23, Salesforce Tower, Sydney, NSW, AUS, 2000

Website

https://www.recce.com.au

Recce Pharmaceuticals Ltd is an Australia-based globally-focused biotechnology company engaged in the development and commercialization of a new class of antibiotics. It operates in only one business segment being research and development of pharmaceutical drugs. The firm operates in three geographic segments being Australia, the United Kingdom, and the United States of America, of which the majority of the revenue comes from Australia. The company offers antibiotic drugs to treat the diseases caused by various bacterias namely Sepsis, Helicobacter Pylori, Escherichia coli, Pseudomonas aeruginosa, and others.

Recce Pharmaceuticals (ASX:RCE) Headlines

No Headlines